within Pharmacolibrary.Drugs.ATC.A;

model A10BK05
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.9,
    Cl             = 0.00019666666666666669,
    adminDuration  = 600,
    adminMass      = 50 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0535,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.008916666666666666,
    Tlag           = 10.200000000000001
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A10BK05</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Ipragliflozin is a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor used for the treatment of type 2 diabetes mellitus. It facilitates urinary glucose excretion and helps lower blood glucose levels. Ipragliflozin is approved and used in several countries for the management of type 2 diabetes.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult subjects following single-dose oral administration.</p><h4>References</h4><ol><li><p>Kadokura, T, et al., &amp; Smulders, R (2014). Clinical pharmacokinetics and pharmacodynamics of the novel SGLT2 inhibitor ipragliflozin. <i>Clinical pharmacokinetics</i> 53(11) 975–988. DOI:<a href=\"https://doi.org/10.1007/s40262-014-0180-z\">10.1007/s40262-014-0180-z</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/25316572/\">https://pubmed.ncbi.nlm.nih.gov/25316572</a></p></li><li><p>Alkabbani, W, &amp; Gamble, JM (2021). Profile of Ipragliflozin, an Oral SGLT-2 Inhibitor for the Treatment of Type 2 Diabetes: The Evidence to Date. <i>Drug design, development and therapy</i> 15 3057–3069. DOI:<a href=\"https://doi.org/10.2147/DDDT.S281602\">10.2147/DDDT.S281602</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34285473/\">https://pubmed.ncbi.nlm.nih.gov/34285473</a></p></li><li><p>Zhang, W, et al., &amp; Smulders, R (2013). The effect of moderate hepatic impairment on the pharmacokinetics of ipragliflozin, a novel sodium glucose co-transporter 2 (SGLT2) inhibitor. <i>Clinical drug investigation</i> 33(7) 489–496. DOI:<a href=\"https://doi.org/10.1007/s40261-013-0089-6\">10.1007/s40261-013-0089-6</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/23733389/\">https://pubmed.ncbi.nlm.nih.gov/23733389</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A10BK05;
